Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bridging integrator 1 (BIN1) is a nucleocytoplasmic adaptor protein encoded by the BIN1 gene. It belongs to the BAR adapter family of proteins that regulate membrane curvature and remodeling. Multiple isoforms exist due to alternative splicing; these isoforms have tissue-specific functions in the central nervous system, muscle cells, heart tissue, immune cells, and more. In neurons it participates in synaptic vesicle endocytosis; in muscle it is essential for T-tubule formation critical for excitation-contraction coupling. BIN1 acts as a tumor suppressor by interacting with c-MYC to inhibit its transcriptional activity. Loss or mutation of BIN1 has been implicated as a genetic risk factor for late-onset Alzheimer’s disease—likely through disruption of tau homeostasis at synapses—and causes various inherited skeletal myopathies characterized by progressive muscle weakness. In cancer biology it is frequently silenced or misspliced during malignant progression. The structure includes an N-terminal BAR domain responsible for membrane binding/tubulation and a C-terminal SH3 domain mediating interactions with other proteins such as phospholipase D isoforms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bridging integrator 1 (BIN1).